SERUM PSA AS A TUMOR MARKER FOR PATIENTS UNDERGOING DEFINITIVE RADIATION THERAPY
- 1 November 1993
- journal article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 20 (4) , 737-747
- https://doi.org/10.1016/s0094-0143(21)00926-5
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancerCancer, 1993
- Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Serum prostate-specific antigen: the most useful tumor marker.Journal of Clinical Oncology, 1992
- Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapyRadiotherapy and Oncology, 1992
- Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapyRadiotherapy and Oncology, 1992
- A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapyCancer, 1991
- A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1990
- Effect of external beam radiation therapyon serum prostate-specific antigenUrology, 1990
- Prostatc specific antigen as an indicator of response to radiotherapy in prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1989
- The role of radiation therapy in stages A2 and B adenocarcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1988